Abstract: The present invention refers to a process for the asymmetric synthesis of isopiperitenol and successor compounds.

Abstract: A control method for a continuously variable valve lift mechanism includes: controlling a continuously variable valve lift mechanism to enter a limp mode when the continuously variable valve lift mechanism fails and disables an automatic valve lift changing function; driving and forcing the continuously variable valve lift mechanism to move to a maximum lift position; and triggering a self locking function to self lock the continuously variable valve lift mechanism at the maximum lift position when the continuously variable valve lift mechanism reaches the maximum lift position. A control system for a continuously variable valve lift mechanism, and a vehicle are also provided.

Abstract: A data processing method based on a container engine and a related device are provided. The data processing method includes: acquiring, in response to a creation request for an isolation container, creation dependency resource information of the isolation container; performing validity verification on the creation dependency resource information based on a valid policy file of a container engine corresponding to the isolation container, to obtain a validity verification result of the isolation container; and creating the isolation container when the validity verification result is a valid result.

Abstract: The present invention discloses a plant fertility-associated protein and its application. The present invention claims a method for obtaining male-sterile plants by reducing or inhibiting the activity and/or content of GmMS1 protein in the target plants. The present invention also claims a method for obtaining male-sterile plants by silencing or suppressing the expression of GmMS1 gene or knocking out the GmMS1 gene in the target plants. The present invention is of great significance to the research of plant fertility and the breeding of sterile plants.

Abstract: A valve mechanism includes a valve, a camshaft, an intermediate swing arm located between a cam and the valve, a lift regulating mechanism and a roller assembly. The cam drives the valve to move by means of the intermediate swing arm. The roller assembly is supported by the cam, an eccentric wheel of the lift regulating mechanism and an intermediate swing arm roller. A peripheral surface of the eccentric wheel includes a lift regulating section having a start point and an end point, a maximum lift point of the lift regulating section is located between the start point and the end point, and the lift regulating section is divided into a first section which is convex and a second section having at least a part thereof concave.

Abstract: The present invention relates to chiral phosphoramidimidates, their salts and metal complexes as well as derivatives thereof and their use as catalysts.

Abstract: A valve mechanism includes a valve, a camshaft, a fixed support, an intermediate swing arm and a supporting base. The fixed support is provided with a connecting-portion via hole running from top to bottom, two oil passages are defined in a connecting portion, and each of the oil passages is connected with the connecting-portion via hole and a corresponding intermediate swing arm shaft hole. The supporting base defines first and second oil feeding passages therein, the first supporting-base oil feeding passage is communicated with the connecting-portion via hole, and an upper end of the second supporting-base oil feeding passage extends to a base-body camshaft supporting portion of the supporting base. An engine and a vehicle are also provided.

Abstract: A valve mechanism includes a valve, a camshaft, a fixed support, an intermediate swing arm and a supporting base. The fixed support is provided with a connecting-portion via hole running from top to bottom, two oil passages are defined in a connecting portion, and each of the oil passages is connected with the connecting-portion via hole and a corresponding intermediate swing arm shaft hole. The supporting base defines first and second oil feeding passages therein, the first supporting-base oil feeding passage is communicated with the connecting-portion via hole, and an upper end of the second supporting-base oil feeding passage extends to a base-body camshaft supporting portion of the supporting base. An engine and a vehicle are also provided.

Abstract: A valve mechanism includes a valve, a camshaft, an intermediate swing arm located between a cam and the valve, a lift regulating mechanism and a roller assembly. The cam drives the valve to move by means of the intermediate swing arm. The roller assembly is supported by the cam, an eccentric wheel of the lift regulating mechanism and an intermediate swing arm roller. A peripheral surface of the eccentric wheel includes a lift regulating section having a start point and an end point, a maximum lift point of the lift regulating section is located between the start point and the end point, and the lift regulating section is divided into a first section which is convex and a second section having at least a part thereof concave.

Abstract: A control method for a continuously variable valve lift mechanism includes: controlling a continuously variable valve lift mechanism to enter a limp mode when the continuously variable valve lift mechanism fails and disables an automatic valve lift changing function; driving and forcing the continuously variable valve lift mechanism to move to a maximum lift position; and triggering a self locking function to self lock the continuously variable valve lift mechanism at the maximum lift position when the continuously variable valve lift mechanism reaches the maximum lift position. A control system for a continuously variable valve lift mechanism, and a vehicle are also provided.

Abstract: The present invention relates to chiral phosphoramidimidates, their salts and metal complexes as well as derivatives thereof and their use as catalysts.

Abstract: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Abstract: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Abstract: This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Abstract: This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans, or a pharmaceutically acceptable salt, in vivo hydrolysable ester, enantiomer, diastereomer or mixture thereof: formula (II) represents C6-10 aryl or C3-10 heterocyclyl, said aryl or heterocyclyl optionally substituted with 1-3 groups selected from Ra; Z represents (CH2)nPO(OR)(OR*).

Abstract: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Abstract: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Abstract: This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Abstract: This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans, or a pharmaceutically acceptable salt, in vivo hydrolysable ester, enantiomer, diastereomer or mixture thereof: formula (II) represents C6-10 aryl or C3-10 heterocyclyl, said aryl or heterocyclyl optionally substituted with 1-3 groups selected from Ra; Z represents (CH2)nPO(OR)(OR*).

Abstract: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.